Physician profile
Mark D Erhardt
NPI 1770546640
$6,498.67
in general payments reported to CMS, 2019-2025
42 companies · $727 in 2025
The $727 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $703 · 2021: $1,237 · 2022: $1,162 · 2023: $1,067 · 2024: $788 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,582.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,445.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $902.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $747.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $503.02 | 2021-2025 | |
| Pfizer INC. | $396.53 | 2019-2025 | |
| Amgen INC. | $306.16 | 2020-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $269.77 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.58 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $217.94 | 2019-2022 | |
| Abbott Laboratories | $216.72 | 2021-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $168.49 | 2019-2021 | |
| Allergan, INC. | $126.82 | 2019-2021 | |
| Amarin Pharma, INC. | $92.50 | 2020-2022 | |
| Glaxosmithkline, LLC. | $84.58 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.12 | 2022-2024 | Xifaxan, Trulance |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Erhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.